The payer's dilemma: Recognizing the uncertainty of clinical and economic evidence at product launch

Journal of Managed Care Pharmacy

Volumn 15, Issue 2, 2009, Pages 167-169

  Watkins, John B ^a   Sullivan, Sean D ^b  

^a Premera Blue Cross   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; INSULIN GLARGINE; PLACEBO;

ADD ON THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULARY; DRUG MARKETING; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; LETTER; MANAGED CARE; PHARMACY AND THERAPEUTICS COMMITTEE; RISK BENEFIT ANALYSIS;

EID: 63349101803     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.2.167     Document Type: Letter

References (16)

1. Curtiss FR, Fairman KA. Diabetes drug therapy - first do no harm. J Manag Care Pharm. 2008;14(7):658-60. Available at: http://www.amcp.org/data/jmcp/658-660_CurtissFairman-Final.pdf.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-87.
3. Pinhas-Hamel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700.
4. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes; losing the relative protection of youth. Diabetes Care. 2003;26:2999-3005.
5. Silva MA, Swanson AC, Gandhi P, et al. Statin-related adverse events: A meta-analysis. Clin Ther. 2006;28(1):26-35.
6. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. J Manag Care Pharm. 2006;12(9):726-35. Available at: http://www.amcp.org/data/jmcp/726-735.pdf.
7. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-100.
8. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-35.
9. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-47.
10. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8(4):419-28
11. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-69.
12. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin. 2004;20(suppl 1):S5-S26.
13. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(suppl l):S27-S40.
14. U.S. Food and Drug Administration. Information for healthcare professionals - exenatide (marketed as Byetta). October 16, 2007. Available at: www.fda.gov/CDER/drug/InfoSheets/HCP/exenatideHCP.htm. Accessed October 13, 2008.
15. Ahmad SR, Swann J. Exenatide and rare adverse events. New Engl J Med. 2008;358(18):1970-71.
16. Exenatide (Byetta) and pancreatitis. Med Lett Drugs Ther. 2008;50 (September 8):69.